Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent seasonal influenza VLP
- Development stage
- Preclinical
- Lead developer
- Medicago
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Quadrivalent seasonal influenza VLP** is a virus-like particle (VLP) vaccine candidate designed to protect against four circulating influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Yamagata and Victoria). Produced using insect cell-based baculovirus expression systems (BEVS), it self-assembles HA (hemagglutinin), NA (neuraminidase), and M1 proteins into non-infectious particles morphologically and antigenically similar to influenza virions (100-180 nm spherical particles with spikes). This egg-independent platform offers advantages in scalability, rapid production, and stability, inducing robust hemagglutination inhibition (HAI) and neutralizing antibody responses comparable to egg-based or recombinant HA vaccines in preclinical mouse models, with potential for annual strain updates to match prevalent seasonal strains.[2][4]
- Other names
- quadrivalent influenza VLPinfluenza virus-like particle vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)HA (Hemagglutinin from influenza A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains)γδ TCR (T-cell receptor)NeuraminidaseM1 (Matrix protein 1)
Beyond the preview
Go deeper on quadrivalent seasonal influenza VLP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent seasonal influenza VLP.